Cellares Raises $50M in Series D Funding from Prime Radiant Partners

The investment was made by Prime Radiant Partners’ Prime Radiant Fund SLP SICAV-RAIF.

The company intends to use the funds to begin commercial-scale operations, pursue an IPO in 2027, and expand its activities in Leiden, the Netherlands.

Cellares’ manufacturing facility, currently under construction in Leiden, Netherlands, is designed to serve drug sponsors across global markets using the same automated manufacturing infrastructure as in the United States. The facility is expected to be GMP-ready in 2027.

Prime Radiants experience in European healthcare services, with offices in Milan, and Munich, will help support Cellares expansion as demand for automated cell therapy manufacturing continues to grow across the region.

Read More:King’s College and eCampus.com Expand Partnership

Cellares is currently running programs across CAR T, TCR-T, and progenitor T cell therapies. Its drug sponsor partners include Bristol Myers Squibb, Cabaletta Bio, TScan Therapeutics, and ProTgen, which are using the Cell Shuttle® platform for both development and commercial manufacturing stages.

“Cell therapy has moved from scientific promise to commercial reality, but the manufacturing infrastructure to support it at scale does not yet exist at the level the market will need,” said Walid Gardezi, Co-Founder and Partner at Prime Radiant Partners. “Cellares is building that infrastructure across the markets where these therapies will be delivered. Our roots in European pharma services give us a meaningful perspective on what it takes to operate in those markets, and we will be active partners in supporting Cellares’ expansion in Europe.”

“A global cell therapy manufacturing network has to be built in all major markets at once,” said Fabian Gerlinghaus, Co-Founder and CEO of Cellares. “Prime Radiant’s operational depth in pharma services across continental Europe makes them a strategic partner as we expand our manufacturing presence in Europe. The investors who have joined this Series D reflect the strength of the platform and the scale of what comes next.”

About Cellares

Founded in 2019 by Fabian Gerlinghaus and Omar Kurdi, Cellares is the first Integrated Development and Manufacturing Organization (IDMO). It provides global cell therapy development and manufacturing services using an Industry 4.0 approach to enable large-scale production of cell therapies. The company helps drug sponsors develop, scale, and commercialize cell therapies with the capacity, reliability, and cost efficiency needed to meet patient demand.

About Prime Radiant Partners

Founded in 2025, Prime Radiant Fund SLP SICAV-RAIF is a Luxembourg-based alternative investment fund. It is advised by Prime Radiant Partners an advisory firm focused on middle market, high growth private equity investments in healthcare and life sciences across North America and Europe.

Read More:Ouster and Benchmark Expand Partnership to Scale Volume Production